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Abstract— Full quantification of regional cerebral metabolic 
rate of glucose (rCMRglu) with [18F]fluorodeoxyglucose 
([18F]FDG) positron emission tomography (PET) imaging 
requires measurement of an arterial input function (AIF) curve, 
which is obtained with an invasive arterial blood sampling 
procedure during the scan. We previously proposed a non-
invasive simultaneous estimation (nSIME) method that quantifies 
binding of a PET radioligand by combining individual electronic 
health records (EHR) information and a pharmacokinetic AIF 
(PK-AIF) model. Initially applied only to [11C]DASB data, in this 
study we validate nSIME for a different radioligand, [18F]FDG, 
adapting the algorithm to the specific distribution and 
metabolism of this radioligand. We evaluate the impact of the 
PK-AIF model, the number of [18F]FDG-specific soft constraints, 
and the type of predictive strategy. The accuracy of nSIME is 
then compared to a population-based approach. All analyses are 
conducted on 67 [18F]FDG PET scans with arterial blood data 
available for comparison. nSIME performance is optimal for 
[18F]FDG when using the PK-AIF model, two soft constraints, 
and an aggregate model to predict the soft constraint values. 
Higher correlation and lower Bland-Altman spread against gold 
standard rCMRglu values based on arterial blood measurements 
are observed for nSIME (r = 0.83, spread = 1.55) compared to the 
population-based approach (r = 0.77, spread = 2.12). nSIME 
provides a data-driven estimation of both amplitude and shape of 
the AIF curve at the individual level and potentially enables non-
invasive quantification of PET data across radioligands, avoiding 
the need for arterial blood sampling. 
 
Index Terms—Arterial input function (AIF), electronic health record 
(EHR), positron emission tomography (PET) imaging 
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I. INTRODUCTION 
ositron emission tomography (PET) allows for in vivo 
measurement of tissue metabolism and neurochemistry 
[1], [2]. [18F]fluorodeoxyglucose ([18F]FDG) is a PET 
radioligand widely used to quantify glucose metabolism for 
the investigation, for example, of tumors and neurological 
disorders such as Alzheimer’s disease [3]–[6].  
Current gold standard full quantification of regional 
cerebral metabolic rate of glucose (rCMRglu) from [18F]FDG 
PET data requires measuring an arterial input function (AIF), 
which is the radioligand concentration level in plasma over the 
duration of the scan, by assaying blood samples acquired from 
an arterial line during scanning. Insertion of an arterial line is 
a relatively invasive procedure with potential complications, 
and the subsequent blood assays are not always reliable, 
adding measurement errors. The procedure is costly, 
discomforting for the patient and exposes clinical staff to 
additional radiation. Consequently, approaches alternative to 
arterial blood sampling have been proposed [7]–[12]. 
Image-derived input function (IDIF) approaches have been 
proposed for [18F]FDG [7], which recover the AIF directly 
from the PET images by identifying cranial blood pools in the 
field of view. These structures are limited in size, and their 
signal is sensitive to motion artifacts and partial volume effect. 
IDIF also requires a fast acquisition protocol of the PET 
images, to accurately recover the initial part of the AIF curve, 
and a few blood samples for calibration of the recovered IDIF. 
Alternatively, population-based input function (PBIF) 
approaches have been validated for [18F]FDG [9]–[12], which 
derive a template AIF curve by normalizing individual AIF 
(obtained via arterial blood sampling) from a large population 
of subjects scanned with the same radioligand. The template is 
then individually calibrated to the subject using a scaling 
factor. PBIF methods rely on the assumption that the AIF has 
a constant shape across subjects, but in fact, kinetic and 
metabolic profiles can vary across individuals [13], [14].  
Simultaneous estimation (SIME) is another promising 
approach that has been validated [15] as an alternative, less 
invasive method for recovering the AIF. SIME is based on a 
mathematical model for the AIF, and estimates the free 
parameters of such model together with the parameters of the 
model that describes the radioligand kinetics in the tissue, by 
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simultaneously fitting multiple brain regions at once. 
However, SIME still requires at least one blood sample to be 
included as a constraint within the algorithm cost function to 
ensure AIF identifiability. Instead of obtaining this blood 
sample, we have shown previously that it may be possible to 
predict the constraint variable from non-invasive patient 
information [16]. More recently, a fully non-invasive SIME 
(nSIME) framework was introduced that combines electronic 
health records (EHR) with dynamic PET data to estimate the 
AIF for [11C]DASB, a radioligand used to image the serotonin 
transporter [17]. Differently from the original SIME [15], 
nSIME adds multiple soft constraints within the algorithm cost 
function, and predicts such constraint variables from EHR and 
PET data using pre-trained models, instead of deriving them 
from the subject blood sample. 
The key innovation of this work is the application of nSIME 
for use with [18F]FDG by adapting, optimizing, and validating 
the algorithm for this radioligand. The utility of EHR-based 
predictions needs in fact to be assessed for each radioligand, 
as the EHR variables predictive of its pharmacokinetics and 
metabolism are not known a priori, and can vary across 
radioligands. Preliminary results of this application were 
published in [18], which is expanded upon here with several 
new technical contributions:  1) comparison of nSIME to gold 
standard quantification; 2) rigorous characterization of both 
SIME and nSIME with one and two constraints using a more 
advanced predictive algorithm; 3) comparison of the proposed 
pharmacokinetic AIF model to the previously used 3-
decreasing exponential model; 4) addition of an AIF curve 
shape selection procedure; and 5) benchmarking nSIME 
against a non-invasive population based approach. 
II. MATERIALS AND METHODS 
A. Subjects and Associated Data 
PET, EHR, and magnetic resonance imaging (MRI) data 
were acquired as part of a study of patients with mild 
cognitive impairment (MCI), mild Alzheimer’s disease (AD) 
and age-matched healthy controls. The study was approved by 
the Institute Review Board of the New York State Psychiatric 
Institute and Columbia University [19]. EHR were collected 
prior to the PET scan and included demographics, clinical 
details, clinical laboratory test results, urinalysis, and vital 
parameters. PET data included regional brain time activity 
curves (TACs), injected dose of [18F]FDG (ID), injected mass 
of [18F]FDG, and radioligand specific activity. The AIF was 
determined using full arterial blood sampling. Eighty-nine 
PET scans were previously acquired from 58 subjects. Only 
scans with a fully sampled AIF, TACs and EHR were included 
in the final dataset, which includes 67 PET scans from 49 
subjects. The 67 scans include 46 baseline and 21 follow-up 
assessments at ~1.5 years (Table I).  
B. PET-related Data Acquisitions and Pre-Processing 
For details of the acquisition protocols, we refer to [19]. 
Briefly, PET images were acquired on an ECAT EXACT HR+ 
scanner (Siemens/CTI, Knoxville, TN). After a 10-minute 
transmission scan, a bolus injection of [18F]FDG (178.4 MBq 
± 9.9 MBq across scans) was administered intravenously. 
Emission data were acquired in 3D mode for 60 minutes with 
26 frames of increasing duration. Images were reconstructed 
on a 128 x 128 matrix (pixel size 2.5 x 2.5 mm2), after 
attenuation and scatter correction. Fourteen arterial blood 
samples were drawn during scan. Samples were centrifuged 
and plasma radioactivity measured using a well counter. Cold 
glucose concentration in blood was measured by a glucometer 
before and after the PET scan, and values averaged. The 
prefrontal cortex (PFC), cingulate (CIN), hippocampus (HIP), 
parahippocampal gyrus (PIP) and grey matter cerebellum 
(CER) were labeled on MRI scans by a trained technician 
[20], [21]. Regions of interest (ROI) masks were transferred to 
motion-corrected and MRI co-registered PET images, and 
TACs extracted as average activity in each ROI over time. The 
sum of mean activity in the whole brain from 2.5 to 10 
minutes post-injection (TACsum) was also derived. A 
preliminary analysis found that TACsum in this time window 
is strongly correlated to [18F]FDG plasma concentration.  
C. EHR Data 
EHR include laboratory data on individual subjects that are 
used to compose a list of 83 initial predictors (Table II). EHR 
measures include demographics, clinical information, clinical 
laboratory test results (chemistry and hematology), urinalysis 
and vital parameters (HR, BP) pre- and post-PET scan. 
TABLE II 
EHR PATIENTS’ DATA USED IN THE  
PREDICTION OF THE CONSTRAINT VARIABLES 
Initial Predictors (N = 83) 
Chemistry (24) Hematology (19) Derived (24) Vitals (9) 
A/G Ratio BasoAbsolute AnionGap BPd Avg 
Albumin Baso% eCO Avg BPd PostScan 
AlkPhos EosinAbsolute MAP Avg BPd PreScan 
ALT(SGPT) Eosin% PP Avg BPs Avg 
AST(SGOT) Hematocrit Blood viscosity BPs PostScan 
BUN Hemoglobin BMI BPs PreScan 
Calcium LymphAbsolute BSA HR Avg 
Chloride Lymph% BUN:Crt ratio HR PostScan 
Cholesterol MCH eCO PostScan HR PreScan 
CO2 MCHC eCO PreScan  
ColdGlu1 MCV eGFR PET (3) 
ColdGlu2 MonoAbsolute eGFRBSA AUCpopul  
Creatinine  Mono% eGFR5 InjectedDose  
Globulin NeutAbsolute eGFR5BSA TACsum  
Glucose Neut% eRMR  
LDH Platelets eTBV Demographics (4) 
MeanGlu RBC eTPV Age 
Phosphorus RDW LBMI Height 
Potassium WBC MAP PostScan Sex 
Sodium  MAP PreScan Weight 
T. Bilirubin  Plasma osmolarity  
Total Protein  PP PostScan  
Triglyceride  PP PreScan  
UricAcid  rCalcium  
 
TABLE I 
DESCRIPTIVE STATISTICS OF THE STUDY POPULATION:  
67 TOTAL PET SCANS FROM 49 SUBJECTS 
Variable Mean (std) Min Max 
Age (years) 68.7 (8.3) 51 87.01 
Sex (# of Male/Female) 28 / 39 
Weight (kg) 74.3  (13.4) 49.0 106.1 
Height (m) 1.67 (0.11) 1.36 1.905 
Injected dose (MBq) 178.4 (9.9) 114 185 
Time EHR-PET (days) 19.46 (18.70) 0 96 
Diagnosis (# subjects): CTR/MCI/AD 23 / 25 / 19 
Scan (#): baseline / follow up 46 / 21 
Baseline – follow up time gap (years) 1.51 (0.31) 1.01 2.15 
EHR = electronic health records, CTR = healthy controls, MCI = mild 
cognitive impairment, AD = Alzheimer’s disease. 
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Average of pre- and post-PET scan values were added for HR, 
and systolic and diastolic blood pressure. Secondary measures 
derived from sex, age, height, weight, and hematocrit include 
body mass index (BMI), body surface area (BSA), estimated 
total blood volume (eTBV), total plasma volume (eTPV), 
estimated resting metabolic rate (eRMR), pulse pressure (PP), 
mean arterial pressure (MAP), and estimated cardiac output 
(eCO), which approximates the stroke volume (SV). 
Glomerular filtration rate (eGFR) was calculated using blood 
urea nitrogen (BUN) and albumin (Albumin), and adjusted for 
individual BSA [22]. Standard clinical formulae were used for 
the calculation of albumin-corrected calcium (rCalcium), 
blood viscosity, anion gap, BUN:Creatinine (BUN:Crt) ratio 
and plasma osmolarity [17]. 
For each scan, a PBIF was also derived from height and 
weight according to the approach proposed in [23], and the 
area under the curve of such PBIF included as an additional 
potential predictor variable (AUCpopul). Of specific interest 
was whether this variable would be selected in the final 
predictive algorithm as part of the general comparison of 
nSIME against the PBIF based approach. 
D. Gold standard rCMRglu 
A two-tissue irreversible compartmental model is fit to each 
ROI TAC separately, using the arterial-blood-based AIF [24]. 
Estimates of the model free parameters are obtained by 
minimizing the error between measured data and TAC fit 
using a non-linear least squares estimator. rCMRglu is then 
calculated as a function of the model parameters. 
 
E. Pharmacokinetic AIF Model 
nSIME uses a mathematical model to describe the AIF (Cp), 
which is common across all brain ROIs. The free parameters 
of the AIF model are estimated together with those describing 
the radioligand kinetics in tissue by fitting TACs from 
multiple ROIs simultaneously. The original implementation of 
SIME [15] used a 3E-AIF model, which fits a straight line to 
the peak (infusion phase), followed by a combination of three-
exponentials after the peak (elimination phase). For nSIME, 
we previously introduced a pharmacokinetic (PK) model for 
the AIF, where infusion and elimination phases are both non-
linear and share parameters, for a more physiologically 
accurate description of drug delivery [17]. Specifically, we 
used the three-compartment PK model reported in Equation 
(1), where θPK = [Bl,λl,td,T] denotes the vector of free 
parameters of the model, Bl is a scaling constant, λl is the rate 
constant of the lth compartment, td is the radioligand infusion 
delay and T is the infusion duration. 
 
𝐶!!" 𝑡 θ!" =
𝐵! 𝑒!!! !!!! − 1!!!!           , 𝑡 < 𝑇
𝐵! 𝑒!!!! − 1 𝑒!!! !!!!!!!! , 𝑡 ≥ 𝑇
 (1) 
 
The PK-AIF model was fitted to the arterial blood-derived 
measurements for all scans, to derive physiological ranges for 
the parameters in θPK, which are used as parameter bounds 
(minimum and maximum physiological values) and as initial 
parameter estimates (mean physiological values) within the 
nSIME algorithm.  
 
F. Non-invasive Simultaneous Estimation (nSIME) 
Differently from the gold standard approach, SIME fits 
multiple TACs at once and requires only one blood sample 
acquired at some time point post-injection. The optimal 
sampling time is radioligand-specific, and for [18F]FDG is 40 
minutes post-injection [15]. The AIF value at this time point is 
referred to here as AIF40. nSIME removes the need for 
acquiring any blood sample by incorporating a predicted value 
of AIF40 (pAIF40) as a constraint variable within its cost 
function. The predicted area under the curve of the AIF 
(pAUC), derived from the integration of the estimated AIF 
model, is introduced as a second constraint variable for 
nSIME to improve robustness and accuracy of the estimation 
process originally proposed [15]. While AIF40 describes one 
aspect of the AIF curve shape (tail height), the AUC captures 
characteristics of the global shape and scaling, and provides a 
more stable measure as it is calculated from multiple time 
points [17]. The soft constraint variables pAIF40 and pAUC 
are incorporated into the nSIME cost function described in (2).  
 
Φ 𝑡, θ!" ,Ψ!!"# ,… ,Ψ!!"# =





𝑣[𝑝𝐴𝐼𝐹40 − 𝐶!(𝑡!"#|θ)]! + 𝑧[𝑝𝐴𝑈𝐶 − 𝐴𝑈𝐶(θ)]! (2)  
 
The first term in Equation (2) minimizes over R ROIs and J 
time points the squared distance between the measured TAC, 
Yrj, and the TAC predicted by the model, C(tj|θ,Ψr), where θ  
and Ψr are the parameters of AIF and [18F]FDG kinetic models 
for the rth ROI, respectively. The second term represents the 
soft constraint on AIF40, as the difference between pAIF40 
and the corresponding value in the AIF model at time topt = 40 
min, Cp(topt|θ). The third term is the soft constraint on AUC, 
given as the difference between pAUC and the AUC of the AIF 
curve model Cp(t|θ). The weights v and z balance fitting of the 
observed TACs and adherence of the modeled AIF to the two 
constraints (v = 100 and z = 5, as suggested in [17]). As done 
previously for [18F]FDG [15], 5 ROIs (CER, CIN, HIP, PFC 
and PIP) were used within nSIME. 
rCMRglu can then be estimated for each ROI from the Ψr 




, where LC is the 
lumped constant (assumed equal to 0.65 here [25]) that 
converts rates of [18F]FDG uptake and phosphorylation into 
rates of glucose use, and K1, k2, k3 are the micro-parameters of 
the [18F]FDG kinetic model in tissue.  
G. Selection of EHR-based Predictors  
The soft constraint variables pAIF40 and pAUC were 
predicted from EHR data only, using multiple linear 
regression models identified through a predictive algorithm. 
Initially, a screening procedure was applied to the whole set of 
EHR predictors (Table II) to select variables that are more 
strongly correlated to ground-truth measures Cp(topt|θ) and 
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AUC(θ). The procedure uses squared Pearson’s correlation 
coefficient, r2, in linear regressions, with individual EHR 
variables as the predictors, and the ground-truth measure as 
the response variable.   
This screening process is divided into 3 main steps [17] and 
runs separately for response variables Cp(topt|θ) and AUC(θ), 
thus obtaining a set of potential predictors for each constraint: 
1) each predictor variable is retained if its correlation r2 with 
the response variable is greater than 0.1; 2) each predictor 
variable is normalized for injected dose and retained if the 
correlation between the normalized and response variable is 
greater than the correlation between the injected dose itself 
and response variable; 3) all possible multiple regression 
models that include two predictors at a time are fitted with and 
without interaction terms, and the interaction term is selected 
if the correlation of the model with the interaction term is 
greater than the correlation of the model with only the two 
predictors. Furthermore, the r2 of the model must be greater 
than 0.3 for Cp(topt|θ), and 0.4 for AUC(θ), and the p-value of 
the interaction term smaller than 0.05.  
H. Predictive Model Design 
We used a predictive algorithm previously described in 
[17], to separately predict pAIF40 and pAUC from EHR data 
only using leave-one-out cross-validation. The aggregated 
model approach selects the regression model with the highest 
bootstrapped correlation to blood-based mAIF40 and mAUC in 
the training data, each time excluding a different scan from the 
training set, and yields multiple models that are then 
aggregated to predict pAIF40 or pAUC. The number of 
predictors in each regression model was limited to two; three- 
and four- variable models were excluded in preliminary 
analyses, as they did not improve prediction accuracy, likely 
due to the small sample size.  
I. Simulated Annealing  
For each scan, nSIME ran using the subject-specific 
predicted pAIF40 and pAUC values, without vascular 
correction of the TACs. Stochastic simulated annealing was 
used to solve the proposed optimization problem [15]. The 
nSIME-derived AIF with the smallest full width half 
maximum (FWHM) across 5 repeated runs was selected 
automatically for calculating rCMRglu. Five runs were used 
because, in some instances, it can take from 1 to 5 runs for 
SIME to converge to parameters that reconstruct an AIF curve 
with a typical physiological shape.  AIF FWHM was 
calculated as the horizontal distance at mid height around the 
peak of the AIF curve. This helps to eliminate AIF curves with 
wide peaks.  
J. Experimental Design and Evaluation Setup 
First, we tested the performance of the aggregate model 
selection in estimating pAIF40 and pAUC. Constraint 
variables predictions were compared against the arterial blood-
derived measured values (mAIF40 and mAUC) using 
Pearson’s correlation coefficients and Bland-Altman (BA) 
plots. Second, we tested whether the PK-AIF model provides a 
better fit of the AIF curve and adds stability within nSIME 
Fig. 2.  Predictive modeling results with the aggregate model. Regression (a, 
c) and BA (b, d) plots of predicted versus ground-truth values from AIF 
arterial blood samples. (a-b): Predicted AIF40 (pAIF40) versus measured 
AIF40 (mAIF40). (c-d): Predicted AUC (pAUC) versus measured AUC 
(mAUC). Regression plots: identity line (solid); regression line (dashed). BA 
plots: solid line is the mean; dashed line is the mean +/- 1.96*(standard 
deviation).      
 
TABLE III 
FREQUENCY OF PREDICTOR VARIABLES APPEARANCE IN MODELS SELECTED 
BY THE AGGREGATE-MODEL PREDICTIVE MODELING APPROACH 














Only variables with a frequency of greater than 3.0% are shown 
Fig. 1.  Validation of PK-AIF modeling for [18F]FDG. PK-AIF fitted curves 
Cp (t|θ) (solid lines) and AIF arterial blood samples (dots) for three different 
representative subjects (green, black and magenta curves). The inset shows a 
detail of the AIF peak at 0-5 minutes.  
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compared to the 3E-AIF model used in [15], [16]. 
Performance was assessed by comparing Pearson’s correlation 
coefficients from the regression analysis of rCMRglu 
estimates obtained with nSIME, using either the 3E-AIF or 
PK-AIF model, with measured mAIF40 as the soft constraint 
variable, compared with using the gold standard blood-based 
AIF. Third, we tested whether adding the second soft 
constraint on pAUC into the nSIME cost function improves 
performance. This was assessed via regression analysis of the 
rCMRglu estimates obtained by nSIME versus those obtained 
with AIF analysis, for the following scenarios: a) nSIME with 
measured mAIF40; b) nSIME with measured mAIF40 and 
mAUC; c) nSIME with predicted pAIF40; d) nSIME with 
predicted pAIF40 and pAUC. Fourth, we compared the 
performance of our method (nSIME with pAIF40 and pAUC) 
to that of the PBIF proposed in [23], by performing a 
regression analysis of rCMRglu estimated using PBIF and 
using our method versus values obtained with the gold 
standard. Finally, we estimated rCMRglu in two additional 
ROIs, parietal (PAR) and precuneus (PCN), which were not 
included among the regions used to estimate the nSIME AIF. 
We also compared the rCMRglu estimates across two 
diagnostic groups: healthy controls (CRT) and AD, using a 
two-sample t-test (significance level 0.05). 
III. RESULTS 
A. Quality of the PK model for AIF applied to [18F]FDG 
 Fits of the PK model in (1) to blood-derived AIF samples are 
illustrated in Fig. 1 for three representative cases. Correlations 
of the derived constraint variables with blood-based values 
are: r = 0.99 for AIF40 and r = 0.99 for AUC. The range of 
values for the PK model parameters θPK obtained in the 
considered cohort were: td [0.49, 1] (min), T [0.19, 1] (min); 
𝐵! [0, 0.5], 𝐵! [0.15, 0.9], 𝐵! [0.54, 2.91] (µCi/mL); 𝑙! [0, 
0.02], 𝑙! [0.21, 1.70], 𝑙! [0.54, 10] (min
-1).  
B. Performance of Predictor Selection  
The screening procedure selected a total of 40 predictors for 
pAIF40 and 38 for pAUC (frequently selected predictors are 
reported in Table III). TACsum, RDW, and ID were frequently 
selected for both constraint variables. Other frequent 
predictors included triglycerides for pAIF40, and BSA and 
ColdGlu2 for pAUC. The aggregate model approach yielded 
the following correlation values between predicted and blood-
based values: r = 0.78 (pAIF40) and r = 0.82 (pAUC). Results 
of the predictions are reported in Fig. 2 as scatter plots and as 
BA plots.  
C. PK-AIF versus 3E-AIF 
Using the PK-AIF model improves correlation between 
nSIME with measured mAIF40 and gold standard rCMRglu 
values (r = 0.89) compared to the 3E-AIF model (r = 0.85), 
and yields a smaller bias, closer to 0 (Fig. 3). Notably, there 
are also fewer outlier errors when the PK-AIF model is used. 
D. Using One Versus Two Constraints 
Using nSIME with blood-based soft constraint values leads 
to correlations between nSIME-derived and AIF-based 
rCMRglu values of r = 0.90 when using only mAIF40 (Fig. 
4a-b) and r = 0.94 when using both mAIF40 and mAUC (Fig. 
4c-d). Moreover, the spread between the 95% limits of 
agreement in the BA plots is reduced from 1.29 to 1.01 when 
using two soft constraints, while biases are similar and close to 
Fig. 3.  TAC rCMRglu estimations using nSIME modeling with the ground-
truth mAIF40 as the constraint variable. Regression (a, c) and Bland-Altman 
(b, d) plots are displayed for: (a-b) rCMRglu obtained with the 3E-AIF 
model; (c-d) rCMRglu obtained with the PK-AIF model. Regression plots: 
identity line (solid), regression line (dashed). BA plots: solid line is the 
mean, dashed line is the mean +/- 1.96*(standard deviation).  
Fig. 4. TAC rCMRglu estimations using PK-AIF nSIME with one or two 
ground-truth soft constraint variables. Regression (a, c) and BA (b, d) plots 
are displayed for: (a-b): nSIME with mAIF40. (c)-d): nSIME with both 
mAIF40 and mAUC. Regression plots: identity line (solid), regression line 




0. Using nSIME with non-invasively predicted soft constraint 
variables leads to correlations between nSIME-derived and 
AIF-based rCMRglu values of r = 0.79 when using only 
pAIF40 (Fig. 5a-b), and r = 0.83 when using both pAIF40 and 
pAUC (Fig. 5c-d). The BA plots spread is reduced from 1.72 
to 1.55 when using two soft constraints, with a slightly higher 
bias equal to 0.15. 
E. Comparison of nSIME with the PBIF approach 
rCMRglu estimates obtained using the population approach 
proposed in [23] are reported in Fig. 6. Compared to nSIME, 
with two predicted soft constraint variables, correlation is 
lower for PBIF (0.77 vs. 0.83), spread is higher (2.12 vs. 
1.55), and bias is higher (0.43 vs. 0.15).  
F. Individual ROI and group analyses 
Correlation between rCMRglu estimated with nSIME and 
those calculated using the gold standard blood-based approach 
are r = 0.759 and r = 0.768 for PAR and PCN, respectively, 
comparable to individual correlations for the five ROIs used to 
estimate the nSIME AIF, r = 0.693-0.798. 
There is a significant difference in rCMRglu between CTR 
and AD groups: for the gold standard approach, CIN (p = 
0.015), PAR (p = 0.0004), and PCN (p = 0.0005); for nSIME, 
CIN (p = 0.016), PAR (p = 0.00006), and PCN (p = 0.0002).  
IV. DISCUSSION 
In this study we extended the use of nSIME to [18F]FDG, 
with the goal of eliminating the need for arterial blood 
sampling during PET scanning. Our results indicate that the 
nSIME framework can accurately quantify rCMRglu from 
[18F]FDG data, outperform the population based approach, and 
achieve comparable group discrimination to the gold standard. 
High correlations with arterial blood-derived values were 
achieved with the aggregate predictive model from [17]. The 
predictors that most frequently appeared for both constraints 
were TACsum, RDW, and ID. Triglycerides were also 
frequently included for prediction of pAIF40, whereas 
weight/height-derived variables (e.g., BSA, eRMR, eTPV) and 
ColdGlu2 were more important for predicting pAUC. The ID 
is directly related to the distribution of the radioligand in the 
blood. BSA may impact the volume of blood into which the 
radioligand is diluted, and has been used in the past as a 
normalization factor for the AIF [10], [26] and to predict other 
blood-related anchor values [16]. Notably, the relationship 
between weight/height-derived variables and AUC has already 
been identified in [17] for [11C]DASB. An interesting finding 
is the selection of RDW and triglycerides, which were not 
identified as predictors for [11C]DASB. One possible 
explanation is that RDW is related to metabolic balance and 
red blood cell homeostasis [27] and thus partially reflects each 
subject metabolic profile. Triglycerides have been associated 
with inflammation-related [18F]FDG uptake in arterial plaques 
[28], which could influence blood availability of the 
radioligand, especially in the older MCI and AD subjects in 
this study. Triglycerides may also affect lipid membrane 
composition and thus a variety of cellular functions that in 
turn could impact glucose uptake and utilization. Finally, 
unlike [11C]DASB, HR and BP do not appear to be relevant for 
[18F]FDG-based prediction, possibly because [18F]FDG is 
metabolized throughout the body whereas [11C]DASB is 
primarily metabolized by the liver.  
It should be noted that both data collection and subject 
inclusion criteria were not specifically designed for this 
retrospective analysis. Furthermore, EHR data used in this 
study were gathered within hours to months before the PET 
scan, therefore limiting the accuracy of our analysis. A 
prospective data collection could contribute to even more 
accurate prediction and to fewer outliers, thus improving 
overall performance of the proposed non-invasive method.  
In a separate analysis (data not shown), we compared the 
performance of the aggregate model with that of a simplified 
approach, which selects just a single regression model with the 
highest bootstrapped correlation. We found that the aggregate 
model yields slightly better performance, consistent with our 
Fig. 5. TAC rCMRglu estimations using PK-AIF nSIME with one or two 
predicted soft constraint variables. Regression (a, c) and BA (b, d) plots are 
displayed for: (a-b): nSIME with pAIF40. (c)-d): nSIME with both pAIF40 
and pAUC. Regression plots: identity line (solid), regression line (dashed). 
BA plots: solid line is the mean, dashed line is the mean +/- 1.96*(standard 
deviation).  
 
Fig. 6. TAC rCMRglu estimations using the population-based approach. 
Regression (a) and BA plots (b) are shown. Regression plots identity line 
(solid), regression line (dashed). BA plots: solid line is the mean, dashed line 
is the mean +/- 1.96*(standard deviation).  
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previous results with [11C]DASB. 
Our findings support the use of the PK-AIF model rather 
than a 3E-AIF model, as it yields an improvement in nSIME 
performance itself. The inclusion of the AUC as a second soft 
constraint into the nSIME cost function significantly improved 
the algorithm performance for estimating rCMRglu. Indeed, 
constraining not only the AIF at a specific time point (AIF40), 
but also its overall AUC, aids in accurately reconstructing the 
shape of each individual AIF curve, making nSIME a more 
personalized approach compared to other methods for non-
invasive estimation of AIF. nSIME also outperformed the 
PBIF approach, showing higher correlation and lower spread 
and bias in the rCMRglu estimates vs. gold standard values. 
Individual ROI results show that nSIME is applicable to 
ROIs beyond those that are used to estimate the AIF. Group 
analyses suggest that discrimination between CTR and AD is 
comparable between nSIME and the gold standard. 
The technical contributions presented here enabled nSIME 
to be adapted for accurate quantification of the [18F]FDG 
radioligand, by demonstrating that using two constraints, the 
PK-AIF model, and the AIF curve shape selection improves 
overall performance against the gold standard and also 
outperforms a non-invasive population based approach. 
nSIME shows potential for future research and clinical 
application, as it eliminates the need for arterial blood 
sampling or for the estimation of spillover and recovery 
coefficients as in the case of IDIF methods.  
V. CONCLUSION 
We propose a totally non-invasive nSIME approach for the 
estimation of [18F]FDG rCMRglu values from brain PET 
images that takes advantage of pharmacokinetic theory, health 
record data and predictive algorithms. The advantage of using 
nSIME over a population-based input function approach is 
demonstrated. The high correlation values and small bias in 
quantification errors support the applicability of nSIME to the 
widely used [18F]FDG radioligand and should be investigated 
further in specific prospective studies and additional 
radioligands. Our results advocate for the development of 
larger databases of PET images, and of radioligand blood 
sampling and EHR data, as part of a more general push toward 
a big-data approach in quantitative PET imaging. 
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